Please ensure Javascript is enabled for purposes of website accessibility

This Nasdaq Vaccine Stock Just Got a Big Boost -- and Another Nasdaq Vaccine Stock Deserves the Credit

By Dan Caplinger - Jul 16, 2021 at 12:29PM

Key Points

  • The Nasdaq moved modestly lower on Friday morning.
  • One COVID-19 vaccine maker's stock jumped sharply.
  • The jump wouldn't have happened had it not been for another vaccine stock's strategic moves.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Find out why a big index move is so interesting for investors.

Investors have been anxious this week, creating stock market volatility. That hurt the Nasdaq Composite (^IXIC 0.00%), which was down about 0.3% as of 11:15 a.m. EDT on Friday.

Yet the biggest news on the Nasdaq came from a big winner in the biotech field. Many investors have looked at Moderna (MRNA -4.99%) as the ultimate COVID-19 vaccine success story from an investment perspective, as its vaccines have already helped tens of millions of people around the world. On Friday, Moderna's stock got a boost from a move that has nothing to do with its fundamental business -- and it would never have happened had it not been for the decision of one of its biggest rivals on the vaccine stock front.

Medical professional gives a shot to a patient.

Image source: Getty Images.

S&P makes its latest move

Moderna's stock was up almost 9% late Friday morning. The move came amid news that the biotech will join one of the world's most-followed stock benchmarks.

S&P Dow Jones Indices announced that Moderna will be added to the S&P 500 Index effective before the beginning of trading on Wednesday, July 21. The addition makes sense intuitively, given that the vaccine maker's market capitalization has shot well above $100 billion after its recent success.

Interestingly, it was another COVID vaccine maker that set the stage for Moderna's invitation into the elite index. It will replace Alexion Pharmaceuticals (ALXN), whose $40 billion market capitalization stems largely from its Soliris treatment for generalized myasthenia gravis.

The replacement isn't happening because S&P has any problem with Alexion. It's because AstraZeneca (AZN -0.10%) is set to close on its long-planned acquisition of Alexion in the near future. S&P routinely makes additions and deletions to its index products when mergers and acquisitions are imminent.

Old vs. new

The irony, of course, is that AstraZeneca is also a key provider of a COVID vaccine. It hasn't been high on the radar of U.S. investors because the company hasn't gotten Emergency Use Authorization (EUA) from the Food and Drug Administration for its COVID vaccine. Indeed, AstraZeneca is now contemplating skipping the EUA process entirely and simply requesting full approval for its vaccine from the FDA.

That didn't stop the U.S. government from committing to buy hundreds of millions of doses of AstraZeneca's vaccine. But without approval to use it in the U.S., the government has shipped it to other countries, sometimes as a donation for those in need. Moreover, troubling side effects have raised controversies in other areas where the AstraZeneca vaccine has seen wider use.

It's important for investors to remember, though, that AstraZeneca has a lot more going on than just its COVID vaccine development. The drugmaker already has a lot of unrelated treatments on the market, including blockbusters like oncology drug Tagrisso and asthma/COPD fighter Symbicort.

By contrast, Moderna's COVID vaccine has been its introduction to the market. It has a pipeline of other candidates and a promising future, but Moderna hasn't proved itself the same way that AstraZeneca has.

What's next for Moderna?

Unlike with some high-profile additions to the S&P, investors aren't going to have to wait a month for Moderna to be added to the index. That should minimize the artificial impact of the addition on the stock price. The company can expect to see its stock keep trading on the prospects for its vaccine and future products.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$167.96 (-4.99%) $-8.82
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
^IXIC
$13,128.05 (0.00%) $0.00
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.74 (-0.10%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.